House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Pulmonology

Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)

NICE · 2024 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

BTS, NICE and SIGN NG245 covers objective asthma diagnosis, monitoring and chronic treatment across age groups. It separates adult and childhood diagnostic thresholds and uses different initial and escalation pathways for people aged 12 or older, children aged 5–11 and preschool children. Before escalation it requires attention to adherence, inhaler technique and alternative explanations; education and a personal action plan accompany treatment.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Confirm the diagnosis and assess context

  • Do not confirm asthma from symptoms alone: require a suggestive history and supporting objective test, recording the basis of the diagnosis. A normal examination does not exclude asthma; prior inhaled corticosteroids can make spirometry and FeNO results appear normal. Children under 5 follow the suspected-asthma treatment and regular-review pathway; attempt objective tests from age 5 if symptoms persist. [1]
  • Treat acute illness or marked symptoms immediately. If objective testing cannot be done at presentation, test after the acute symptoms are controlled and advise urgent contact if the person worsens while waiting. [1]
  • In adult-onset, poorly controlled or recurrent childhood asthma, ask whether symptoms improve away from work or on holiday, record the answers and refer suspected occupational asthma to a specialist. [1]

Use age-specific objective tests

  • For adults with a suggestive history, diagnose asthma if blood eosinophils exceed the laboratory range or FeNO is at least 50 ppb. If these do not confirm it, perform spirometric reversibility: the criterion is an FEV1 rise of at least 12% and 200 mL, or at least 10% of predicted FEV1. [1]
  • If adult spirometry is unavailable or delayed, record PEF twice daily for 2 weeks; variability expressed as amplitude percentage mean of at least 20% supports diagnosis. If suspicion remains despite negative objective tests, refer for bronchial challenge and diagnose when hyper-responsiveness is present. [1]
  • For children aged 5–16 with a suggestive history, FeNO of at least 35 ppb supports diagnosis. If FeNO is not raised or unavailable, use spirometric reversibility: an FEV1 rise of at least 12% from baseline or at least 10% of predicted normal. [1]
  • For children whose diagnosis remains uncertain after testing, seek paediatric specialist review, potentially including bronchial challenge. A preschool child needs respiratory paediatric referral after a wheeze-related hospital admission or at least 2 emergency-department admissions within 12 months. [1]

Check treatment delivery before escalation

  • Before increasing treatment, address alternative diagnoses, comorbidities, adherence, inhaler technique and relevant exposures. Do not prescribe a short-acting beta agonist without an accompanying inhaled corticosteroid prescription at any age. [1]
  • Choose an inhaler the person can use, respecting preferences and the environmental impact of suitable devices. Usually add a spacer to a metered-dose inhaler, particularly for children, and observe technique at reviews and when control worsens or a device changes. [1]
  • After starting or adjusting treatment, review the response in 8–12 weeks. At every review, assess symptoms, reliever use, oral steroid courses, absence from school or work and emergency or hospital care. [1]

Treatment from age 12

  • For newly diagnosed asthma from age 12, offer low-dose ICS/formoterol as needed for relief, termed anti-inflammatory reliever therapy. If highly symptomatic or presenting with a severe exacerbation, start low-dose maintenance-and-reliever therapy alongside indicated acute treatment. [1]
  • For patients aged 12 or older whose asthma is uncontrolled on as-needed low-dose ICS/formoterol, offer low-dose MART. If low-dose MART is insufficient, offer moderate-dose MART. [1]
  • For people aged 12 and over, when moderate-dose MART fails despite good adherence, check FeNO if available and blood eosinophils; refer to a specialist if either is raised. If neither is raised, consider an add-on LTRA or LAMA trial for 8–12 weeks, unless adverse effects occur. [1]
  • For people aged 12 and over, refer for specialist care if control remains inadequate despite moderate-dose MART and trials of both LTRA and LAMA. When using montelukast, follow the warning about neuropsychiatric reactions. [1]

Use the separate childhood pathways

  • For newly diagnosed asthma aged 5–11, offer twice-daily paediatric low-dose ICS with SABA as needed. If control is inadequate and the child can manage MART, consider paediatric low-dose MART, then moderate-dose MART if necessary. [1]
  • For a child aged 5–11 unable to manage MART, consider an 8–12-week LTRA trial added to low-dose ICS and SABA, stopping it if ineffective. Refer when control remains inadequate on paediatric moderate-dose MART or moderate-dose ICS/LABA, with LTRA use determined by prior response. [1]
  • In suspected asthma under age 5, consider an 8–12-week trial of twice-daily low-dose paediatric ICS with SABA for relief when maintenance treatment is indicated or severe wheezing episodes occur. [1]
  • If preschool symptoms persist during the treatment trial, check technique, adherence, environmental causes and alternative diagnoses. Refer to a specialist when these do not explain the lack of response. [1]
  • If preschool symptoms resolve after the trial, consider stopping ICS and SABA at 8–12 weeks and review after another 3 months. Recurrence or an episode needing systemic steroids or hospitalisation warrants restarting regular ICS with SABA and subsequent reassessment. [1]

Action plans, step-down and pregnancy

  • Offer a documented personalised action plan and education from age 5; symptom-based plans are usually preferred for children. Review understanding at annual review, acute consultations and hospital admission. [1]
  • When control is sustained, discuss the risks and benefits of reducing maintenance treatment. Agree monitoring, update the action plan and allow at least 8–12 weeks between reductions. [1]
  • Review asthma early in pregnancy and postpartum and emphasise continued treatment to maintain control. Offer oral corticosteroids when needed for an exacerbation, explaining that benefits outweigh risks; do not stop needed LTRA or LAMA solely because of pregnancy. [1]

Limitations and use

  • This is a selected chronic-management summary, not a complete acute-asthma protocol. The full childhood diagnostic sequence, conventional escalation alternatives and product-specific dose tables remain in the guideline.
  • Device licences, strengths and permitted ages vary. The source notes that not every ICS/formoterol device is licensed for AIR or MART; check the specific product and local availability.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
27 November 2024
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Confirm the diagnosis and assess context
  • Use age-specific objective tests
  • Check treatment delivery before escalation
  • Treatment from age 12
  • Use the separate childhood pathways
  • Action plans, step-down and pregnancy
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House